<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 获取免费报告) 的股价在周一交易中达到了新的 52 周高点，此前花旗集团将该股票的目标价从 45.00 美元上调至 50.00 美元。花旗集团目前对该股票给予买入评级。Kiniksa Pharmaceuticals International 的股价最高达到 39.57 美元，最后交易于 39.37 美元，成交量为 280711 股。该股票此前收于 38.64 美元。</p>
<p>其他几家券商也对 KNSA 发布了报告。Zacks Research 在 10 月 6 日的研究报告中将 Kiniksa Pharmaceuticals International 的评级从 “强力买入” 下调至 “持有”。Wall Street Zen 在 10 月 3 日的报告中将 Kiniksa Pharmaceuticals International 的评级从 “强力买入” 下调至 “买入”。Jefferies Financial Group 在 7 月 29 日的报告中将 Kiniksa Pharmaceuticals International 的目标价从 45.00 美元上调至 54.00 美元，并给予该公司 “买入” 评级。Wedbush 在 10 月 13 日的报告中将 Kiniksa Pharmaceuticals International 的目标价从 38.00 美元上调至 44.00 美元，并给予该公司 “跑赢大盘” 评级。最后，TD Cowen 在 9 月 29 日的研究报告中开始覆盖 Kiniksa Pharmaceuticals International 的股票。他们对该股票给予 “买入” 评级，目标价为 60.00 美元。七位股票研究分析师对该股票给予买入评级，两位给予持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 46.86 美元。</p>
<p><strong>查看我们关于 KNSA 的最新研究报告</strong></p>
<h2>内部买卖</h2>
<p>在相关消息中，董事 Thomas Malley 在 8 月 14 日的交易中出售了 78,233 股 Kiniksa Pharmaceuticals International 的股票。该股票以平均价格 33.09 美元出售，总交易额为 2,588,729.97 美元。出售后，该董事直接持有公司 12,546 股股票，价值约 415,147.14 美元。这笔交易代表了他们持股的 86.18% 的减少。该出售在与 SEC 的法律文件中披露，您可以通过此链接访问。此外，内部人士 John F. Paolini 在 8 月 6 日的交易中出售了 29,325 股公司的股票。这些股票以平均价格 32.55 美元出售，总价值为 954,528.75 美元。交易完成后，内部人士持有 57,403 股公司的股票，价值为 1,868,467.65 美元。这笔交易代表了他们持股的 33.81% 的减少。该出售的披露可以在这里找到。内部人士在上个季度共出售了 596,839 股公司股票，价值为 20,357,964 美元。公司内部人士持有 53.48% 的公司股票。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对 KNSA 的持股。GAMMA Investing LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 现在拥有 1,238 股公司股票，价值 27,000 美元，此前在上个季度购买了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度购买了 Kiniksa Pharmaceuticals International 的新头寸，价值 301,000 美元。Asset Management One Co. Ltd.在第一季度购买了 Kiniksa Pharmaceuticals International 的新头寸，价值 41,000 美元。Wealthquest Corp 在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值约 42,000 美元。最后，AMI Asset Management Corp 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 现在拥有 77,688 股公司股票，价值 1,725,000 美元，此前在此期间又收购了 26,010 股。53.95% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>Kiniksa Pharmaceuticals International 的价格表现</h2>
<p>该公司的市值为 29 亿美元，市盈率为 981.10，贝塔值为 0.16。公司的 50 日简单移动平均为 35.85 美元，200 日简单移动平均为 29.82 美元。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近在 7 月 29 日发布了季度财报。公司报告每股收益（EPS）为 0.23 美元，超出市场共识预期的 0.18 美元，超出幅度为 0.05 美元。Kiniksa Pharmaceuticals International 的净利润率为 0.90%，股本回报率为 1.05%。公司季度收入为 1.568 亿美元，而分析师预期为 1.4521 亿美元。Kiniksa Pharmaceuticals International 已将其 2025 财年的指引设定为每股收益。分析师预计 Kiniksa Pharmaceuticals International, plc 在当前财年将发布-0.55 美元的每股收益。</p>
<h2>关于 Kiniksa Pharmaceuticals International</h2>
<p>(获取免费报告)</p>
<p>Kiniksa Pharmaceuticals, Ltd.是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，以满足全球患有重大未满足医疗需求的虚弱疾病患者的需求。其产品候选包括 ARCALYST，一种针对复发性心包炎的白细胞介素-1α和白细胞介素-1β的治疗药物，这是一种炎症性心血管疾病；Mavrilimumab，一种单克隆抗体抑制剂，已完成针对巨细胞动脉炎的二期临床试验；Vixarelimab，一种单克隆抗体，正在进行针对结节性瘙痒症的 2b 期临床试验，这是一种慢性炎症性皮肤病；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应的关键 T 细胞共刺激信号。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Kiniksa Pharmaceuticals International</li>
<li>最佳航空航天股票投资</li>
<li>5 只令人惊讶的股票，将从未来的机器人热潮中受益</li>
<li>如何投资 FAANG 股票</li>
<li>3 只被低估的大型股，看起来适合反弹</li>
<li>股票中的死亡交叉是什么？</li>
<li>Meta 与 OpenAI：Sora 是否对 Meta 的主导地位构成真正威胁？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Kiniksa Pharmaceuticals International 吗？</h2>
<p>在考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
<p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KNSA

<p>Kiniksa Pharmaceuticals International（纳斯达克代码：KNSA）在花旗集团将其目标价从 45 美元上调至 50 美元并维持买入评级后，达到了 39.57 美元的新 52 周高点。其他分析师的评级则各有不同，Zacks 将评级下调至持有，而 Jefferies 则将目标价上调至 54 美元。内部人士最近出售了大量股份，机构投资者持有 53.95% 的股份。Kiniksa 报告的季度每股收益为 0.23 美元，超出预期，市值为 29 亿美元，市盈率为 981.10</p>

<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Monday after Citigroup raised their price target on the stock from $45.00 to $50.00. Citigroup currently has a buy rating on the stock. Kiniksa Pharmaceuticals International traded as high as $39.57 and last traded at $39.37, with a volume of 280711 shares. The stock had previously closed at $38.64.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 获取免费报告) 的股价在周一交易中达到了新的 52 周高点，此前花旗集团将该股票的目标价从 45.00 美元上调至 50.00 美元。花旗集团目前对该股票给予买入评级。Kiniksa Pharmaceuticals International 的股价最高达到 39.57 美元，最后交易于 39.37 美元，成交量为 280711 股。该股票此前收于 38.64 美元。</p>
</div><p>Several other brokerages have also issued reports on KNSA. Zacks Research lowered Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 6th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Friday, October 3rd. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, July 29th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, October 13th. Finally, TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a &#34;buy&#34; rating and a $60.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $46.86.</p>
<div class="lb-trans"><p>其他几家券商也对 KNSA 发布了报告。Zacks Research 在 10 月 6 日的研究报告中将 Kiniksa Pharmaceuticals International 的评级从 “强力买入” 下调至 “持有”。Wall Street Zen 在 10 月 3 日的报告中将 Kiniksa Pharmaceuticals International 的评级从 “强力买入” 下调至 “买入”。Jefferies Financial Group 在 7 月 29 日的报告中将 Kiniksa Pharmaceuticals International 的目标价从 45.00 美元上调至 54.00 美元，并给予该公司 “买入” 评级。Wedbush 在 10 月 13 日的报告中将 Kiniksa Pharmaceuticals International 的目标价从 38.00 美元上调至 44.00 美元，并给予该公司 “跑赢大盘” 评级。最后，TD Cowen 在 9 月 29 日的研究报告中开始覆盖 Kiniksa Pharmaceuticals International 的股票。他们对该股票给予 “买入” 评级，目标价为 60.00 美元。七位股票研究分析师对该股票给予买入评级，两位给予持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 46.86 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on KNSA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 KNSA 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 596,839 shares of company stock valued at $20,357,964 over the last quarter. Corporate insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Thomas Malley 在 8 月 14 日的交易中出售了 78,233 股 Kiniksa Pharmaceuticals International 的股票。该股票以平均价格 33.09 美元出售，总交易额为 2,588,729.97 美元。出售后，该董事直接持有公司 12,546 股股票，价值约 415,147.14 美元。这笔交易代表了他们持股的 86.18% 的减少。该出售在与 SEC 的法律文件中披露，您可以通过此链接访问。此外，内部人士 John F. Paolini 在 8 月 6 日的交易中出售了 29,325 股公司的股票。这些股票以平均价格 32.55 美元出售，总价值为 954,528.75 美元。交易完成后，内部人士持有 57,403 股公司的股票，价值为 1,868,467.65 美元。这笔交易代表了他们持股的 33.81% 的减少。该出售的披露可以在这里找到。内部人士在上个季度共出售了 596,839 股公司股票，价值为 20,357,964 美元。公司内部人士持有 53.48% 的公司股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. GAMMA Investing LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $301,000. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth about $42,000. Finally, AMI Asset Management Corp raised its stake in Kiniksa Pharmaceuticals International by 50.3% in the 1st quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对 KNSA 的持股。GAMMA Investing LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 现在拥有 1,238 股公司股票，价值 27,000 美元，此前在上个季度购买了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度购买了 Kiniksa Pharmaceuticals International 的新头寸，价值 301,000 美元。Asset Management One Co. Ltd.在第一季度购买了 Kiniksa Pharmaceuticals International 的新头寸，价值 41,000 美元。Wealthquest Corp 在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值约 42,000 美元。最后，AMI Asset Management Corp 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 现在拥有 77,688 股公司股票，价值 1,725,000 美元，此前在此期间又收购了 26,010 股。53.95% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Kiniksa Pharmaceuticals International Price Performance</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 的价格表现</h2>
</div><p>The firm has a market capitalization of $2.90 billion, a PE ratio of 981.10 and a beta of 0.16. The company's fifty day simple moving average is $35.85 and its 200 day simple moving average is $29.82.</p>
<div class="lb-trans"><p>该公司的市值为 29 亿美元，市盈率为 981.10，贝塔值为 0.16。公司的 50 日简单移动平均为 35.85 美元，200 日简单移动平均为 29.82 美元。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 获取免费报告) 最近在 7 月 29 日发布了季度财报。公司报告每股收益（EPS）为 0.23 美元，超出市场共识预期的 0.18 美元，超出幅度为 0.05 美元。Kiniksa Pharmaceuticals International 的净利润率为 0.90%，股本回报率为 1.05%。公司季度收入为 1.568 亿美元，而分析师预期为 1.4521 亿美元。Kiniksa Pharmaceuticals International 已将其 2025 财年的指引设定为每股收益。分析师预计 Kiniksa Pharmaceuticals International, plc 在当前财年将发布-0.55 美元的每股收益。</p>
</div><h2>About Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>关于 Kiniksa Pharmaceuticals International</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd.是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，以满足全球患有重大未满足医疗需求的虚弱疾病患者的需求。其产品候选包括 ARCALYST，一种针对复发性心包炎的白细胞介素-1α和白细胞介素-1β的治疗药物，这是一种炎症性心血管疾病；Mavrilimumab，一种单克隆抗体抑制剂，已完成针对巨细胞动脉炎的二期临床试验；Vixarelimab，一种单克隆抗体，正在进行针对结节性瘙痒症的 2b 期临床试验，这是一种慢性炎症性皮肤病；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应的关键 T 细胞共刺激信号。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>Best Aerospace Stocks Investing</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
<li>How to Invest in the FAANG Stocks</li>
<li>3 Oversold Large-Caps That Look Ripe for a Rebound</li>
<li>What is a Death Cross in Stocks?</li>
<li>Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Kiniksa Pharmaceuticals International</li>
<li>最佳航空航天股票投资</li>
<li>5 只令人惊讶的股票，将从未来的机器人热潮中受益</li>
<li>如何投资 FAANG 股票</li>
<li>3 只被低估的大型股，看起来适合反弹</li>
<li>股票中的死亡交叉是什么？</li>
<li>Meta 与 OpenAI：Sora 是否对 Meta 的主导地位构成真正威胁？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kiniksa Pharmaceuticals International 吗？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kiniksa Pharmaceuticals International（纳斯达克股票代码：KNSA）在分析师上调评级后创下 52 周新高